Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes

por Bowering, K., Harvey, J., Kolaczynski, J. W., Snyder, J. W., Bode, B. W.
Publicado 2018

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL...

por Rodbard, H. W., Bode, B. W., Harris, S. B., Rose, L., Lehmann, L., Jarlov, H., Thurman, J.
Publicado 2016

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with t...

por Bode, B W, Testa, M A, Magwire, M, Hale, P M, Hammer, M, Blonde, L, Garber, A
Publicado 2010

One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial...

por Gough, S. C. L., Bode, B. W., Woo, V. C., Rodbard, H. W., Linjawi, S., Zacho, M., Reiter, P. D., Buse, J. B.
Publicado 2015

Short Report: Treatment Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin asp...

por Bode, B W, Buse, J B, Fisher, M, Garg, S K, Marre, M, Merker, L, Renard, E, Russell-Jones, D L, Hansen, C T, Rana, A, Heller, S R
Publicado 2013